Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 11.3× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SGOV | XBI | |
|---|---|---|
Market Cap | $114.40B | $10.11B |
Volume | 18,879,081 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $100.72 | $169.55 |
52-Week Low | $100.28 | $104.99 |
Typical Hold Time | 50 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.515 with minimal daily movement, reflecting its stable nature. The technical picture is bearish according to moving averages, though oscillators are neutral. Recent corporate actions show consistent dividend payments. Market sentiment is influenced by broader bond market volatility and institutional positioning shifts.
The outlook for SGOV is tied to short-term Treasury yields and Federal Reserve policy. Opportunities include stability and income, but risks involve rising interest rates and institutional selling. Investors should weigh the ETF's defensive role against potential yield compression in a changing rate environment.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
